Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.550 | AlteredExpression | disease | BEFREE | Activation of AR, a major oncogenic driver of PCa, induced the expression of SRD5A1 from twofold to fourfold in three androgen-responsive PCa cell lines. | 28324044 | 2017 | ||||
|
0.550 | GeneticVariation | disease | BEFREE | There were significant associations of genetic polymorphisms in steroid 5α-reductase 1 (SRD5A1) (reference SNPs: rs3736316, rs3822430, rs1560149, rs248797, and rs472402) and SRD5A2 (rs2300700) with the risk of high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial; 2 SNPs were significantly associated with an increased risk (SRD5A1 rs472402 [odds ratio, 1.70; 95% confidence interval, 1.05-2.75; Ptrend = .03] and SRD5A2 rs2300700 [odds ratio, 1.94; 95% confidence interval, 1.19-3.18; Ptrend = .01]). | 27164191 | 2016 | ||||
|
0.550 | Biomarker | disease | BEFREE | To investigate the role of germline variations in cytochrome P450 17A1 (CYP17A1) and steroid-5α-reductase, α-polypeptides 1 and 2 (SRD5A1 and SRD5A2) genes in PCa. | 25960412 | 2015 | ||||
|
0.550 | GeneticVariation | disease | BEFREE | Polymorphisms in the genes SRD5A1 and SRD5A2 encoding androgen biosynthetic 5α-reductase enzymes have been associated with an altered risk of biochemical recurrence after radical prostatectomy in localized prostate cancer. | 24277450 | 2014 | ||||
|
0.550 | AlteredExpression | disease | BEFREE | Our findings suggest that SRD5A1 expression predominates in advanced PC, and that inhibition of SRD5A1 and SRD5A2 together was more effective in reducing cell numbers than inhibition of SRD5A2 alone. | 20519274 | 2010 | ||||
|
0.550 | Biomarker | disease | CTD_human | Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. | 20564326 | 2010 | ||||
|
0.550 | Biomarker | disease | CTD_human | [Dutasteride in the treatment of hormone refractory prostate cancer]. | 18500220 | 2008 | ||||
|
0.550 | Biomarker | disease | RGD | Prostate cancer cells express undetectable to low levels of SRD5A2 but elevated levels of SRD5A1 activity compared with nonmalignant prostatic tissue. | 16818707 | 2006 |